Internationale Publikationen
Hier stellen wir eine Auswahl wissenschaftlicher Veröffentlichungen zur Verfügung, die im Zusammenhang mit der IOZK-Immuntherapie stehen.
Sie können mit Hilfe der Filter eine Auswahl nach Tumorarten und Methoden treffen, oder Suchbegriffe eingeben.
Newcastle disease virus expressing an angiogenic inhibitor exerts an enhanced therapeutic efficacy in colon cancer model
Wilms‘ tumor 1 peptide-loaded dendritic cell vaccination in patients with relapsed or refractory acute leukemia
A comprehensive update to Dendritic Cell therapy for glioma: a systematic review and meta-analysis
Long-Term Feasibility of 13.56 MHz Modulated Electro-Hyperthermia-Based Preoperative Thermoradiochemotherapy in Locally Advanced Rectal Cancer
Molecular Mechanisms of Anti-Neoplastic and Immune Stimulatory Properties of Oncolytic Newcastle Disease Virus
Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
Wilms‘ tumor 1 peptide-loaded dendritic cell vaccination in patients with relapsed or refractory malignant lymphoma
Delayed Effect of Dendritic Cells Vaccination on Survival in Glioblastoma: A Systematic Review and Meta-Analysis
Effects of Modulated Electro-Hyperthermia (mEHT) on Two and Three Year Survival of Locally Advanced Cervical Cancer Patients
Research progress on dendritic cell vaccines in cancer immunotherapy
Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma
GP96 and SMP30 Protein Priming of Dendritic Cell Vaccination Induces a More Potent CTL Response against Hepatoma
Cancer vaccines as a targeted immunotherapy approach for breast cancer: an update of clinical evidence
A Single-Arm Phase II Study to Evaluate Efficacy and Safety of First-Line Treatment With DCVAC/LuCa, Standard of Care Chemotherapy and Shenqi Fuzheng Injection in Advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer Patients
Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial
Safety and efficacy of dendritic cell-based immunotherapy (DCVAC/LuCa) combined with carboplatin/pemetrexed for patients with advanced non-squamous non-small-cell lung cancer without oncogenic drivers
Final results regarding the addition of dendritic cell vaccines to neoadjuvant chemotherapy in early HER2-negative breast cancer patients: clinical and translational analysis
Baseline immunity predicts prognosis of pancreatic cancer patients treated with WT1 and/or MUC1 peptide-loaded dendritic cell vaccination and a standard chemotherapy
Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy
Oncolytic viruses: A novel treatment strategy for breast cancer